- Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
-
Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T
- KMID: 2537899
- J Gynecol Oncol.
- 2022 Jul;33(4):e55.
- doi: 10.3802/jgo.2022.33.e55
Background Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma... -
- CITED
-
- Close
- SHARE
-
- Close
